Literature DB >> 21816775

Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.

Joseph Y Abrams1, Lawrence B Schonberger, Ermias D Belay, Ryan A Maddox, Ellen W Leschek, James L Mills, Diane K Wysowski, Judith E Fradkin.   

Abstract

CONTEXT: Creutzfeldt-Jakob disease (CJD) caused by contaminated cadaveric pituitary-derived human GH (hGH) has been responsible for hundreds of deaths worldwide. Studies of U.S. National Hormone and Pituitary Program (NHPP) hGH recipients have found CJD only in patients treated before 1977, when a new purification procedure with column chromatography was implemented for hGH extraction.
OBJECTIVE: Our objective was to provide updated information on transmission of CJD to NHPP hGH recipients and determine whether recipients of hGH produced after 1977 had a significantly lower CJD risk than pre-1977 recipients. PATIENTS: A total of 5570 NHPP hGH recipients were included in the study: 2099 in the pre-1977 cohort and 3471 in the post-1977 cohort. MAIN OUTCOME MEASURE: We used probability distribution functions to determine whether the observed number of CJD cases in the post-1977 cohort was significantly fewer than expected if the CJD risk was equal to that of the pre-1977 cohort, controlling for treatment duration and follow-up time.
RESULTS: All 22 CJD cases (diagnosed from 1984-2009) occurred in the pre-1977 hGH recipients. Almost half (47.9%) of pre-1977 recipients had a treatment duration of at least 5 yr compared with only 13.8% for post-1977 recipients. Based on the rates present in the pre-1977 cohort, the probability of observing no cases in the post-1977 cohort by chance alone was low (P = 0.0019).
CONCLUSIONS: Risk of acquiring CJD was significantly lower for post-1977 NHPP hGH recipients than for pre-1977 recipients, suggesting that the new purification procedure in 1977 may have greatly reduced or eliminated CJD agent in hGH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816775     DOI: 10.1210/jc.2011-1357

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.

Authors:  Zane Jaunmuktane; Simon Mead; Matthew Ellis; Jonathan D F Wadsworth; Andrew J Nicoll; Joanna Kenny; Francesca Launchbury; Jacqueline Linehan; Angela Richard-Loendt; A Sarah Walker; Peter Rudge; John Collinge; Sebastian Brandner
Journal:  Nature       Date:  2015-09-10       Impact factor: 49.962

Review 2.  Prion Diseases.

Authors:  Michael D Geschwind
Journal:  Continuum (Minneap Minn)       Date:  2015-12

Review 3.  The importance of ongoing international surveillance for Creutzfeldt-Jakob disease.

Authors:  Neil Watson; Jean-Philippe Brandel; Alison Green; Peter Hermann; Anna Ladogana; Terri Lindsay; Janet Mackenzie; Maurizio Pocchiari; Colin Smith; Inga Zerr; Suvankar Pal
Journal:  Nat Rev Neurol       Date:  2021-05-10       Impact factor: 42.937

4.  Iatrogenic Creutzfeldt-Jakob disease, final assessment.

Authors:  Paul Brown; Jean-Philippe Brandel; Takeshi Sato; Yosikazu Nakamura; Jan MacKenzie; Robert G Will; Anna Ladogana; Maurizio Pocchiari; Ellen W Leschek; Lawrence B Schonberger
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

5.  Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study.

Authors:  Ignazio Cali; Mark L Cohen; Stephane Haik; Piero Parchi; Giorgio Giaccone; Steven J Collins; Diane Kofskey; Han Wang; Catriona A McLean; Jean-Philippe Brandel; Nicolas Privat; Véronique Sazdovitch; Charles Duyckaerts; Tetsuyuki Kitamoto; Ermias D Belay; Ryan A Maddox; Fabrizio Tagliavini; Maurizio Pocchiari; Ellen Leschek; Brian S Appleby; Jiri G Safar; Lawrence B Schonberger; Pierluigi Gambetti
Journal:  Acta Neuropathol Commun       Date:  2018-01-08       Impact factor: 7.801

6.  Iatrogenic Creutzfeldt-Jakob disease from commercial cadaveric human growth hormone.

Authors:  Brian S Appleby; Mei Lu; Alberto Bizzi; Michael D Phillips; Sally M Berri; Madeleine D Harbison; Lawrence B Schonberger
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.